Corporate News – GSK PLC
Recent Trading Performance
- GSK (GSK.L) closed the trading session on Wednesday 21 Oct 2026 at GBP 1,868.00, a rise of 0.73 % from the previous close.
- The share price has moved ‑2.22 % against its level at the end of the previous month.
- The simple moving average over the last 200 days is GBP 1,951.39.
- In the last 24 hours, GBP 9.5 bn worth of GSK shares were traded, against a current supply of 40.1 mn shares.
- Market capitalisation stands at GBP 99.3 bn.
- The 52‑week high was GBP 2,282.00 (18 Feb 2026); the 52‑week low was GBP 1,592.00 (24 Oct 2025).
Regulatory Milestones (October 2026)
- Hibsago (antisense oligonucleotide) received U.S. FDA approval under priority review and breakthrough therapy designation. The drug, used with nucleoside‑analogue therapy, offers a higher likelihood of functional cure for chronic hepatitis B after a six‑month course.
- Jemperli (first‑in‑class immunotherapy) received FDA clearance for adults with MSI‑high or mismatch‑repair‑deficient locally advanced rectal cancer. The approval follows positive results from the AZUR‑1 study, demonstrating durable clinical responses without surgery.
These approvals reinforce GSK’s focus on advanced oncology and viral disease therapies.
Related Stock Activity – Last 24 Hours
| Company | Ticker | Movement | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Dar Global | DAR.L | +0.07 % | USD 6.72 | USD 1.2 bn |
| Lloyds Banking | LLOY.L | ‑1.12 % | GBP 103.25 | GBP 76.9 bn |
| National Grid | NG.L | +1.77 % | GBP 1,208 | GBP 80.5 bn |
| Clarivate | CLVT | +1.14 % | USD 1.79 | USD 1.1 bn |
| Vtex | VTEX | +0.96 % | USD 4.13 | USD 691.1 mn |
Highlights
- Lloyds Banking: Shares fell in line with a broader FTSE 100 decline driven by weak mining and banking performance. A brief online service disruption, linked to a Google Cloud outage, was noted. Despite the dip, Lloyds remains a key component of the market’s most actively traded stocks.
- National Grid: Shares rose modestly amid a broader market downturn, reflecting its stable utilities position. European indices experienced slight declines as investors weighed economic uncertainty.
- Vtex: On 20 Oct 2026, senior officers filed Form 4 notices selling portions of their Class A shares. Transactions involved a few thousand shares at a weighted average price slightly above USD 4.00. Ownership levels remain substantial; no material changes to control were reported.
Company Profile
GSK PLC is a research‑based pharmaceutical company headquartered in Brentford, United Kingdom. It operates in the Health Care sector and focuses on developing, manufacturing, and marketing vaccines, prescription and over‑the‑counter medicines, and health‑related consumer products. GSK’s product portfolio addresses infections, depression, skin conditions, asthma, cardiovascular disease, and cancer. The company is listed on the London Stock Exchange and provides additional information on its website at www.gsk.com .
